Dr. med.
Julie Refardt
Position(s)
Senior physician
Endocrinology, Diabetes and Metabolic Disorders
Institution
University Hospital Basel
Phone +41 61 556 56 18
Julie Refardt
Research Focus
Endocrinology, Metabolism & Developmental Disorders
Area of Research
Neuroendocrinology with a focus on neuroendocrine neoplasms and disturbances of the water & salt homeostasis
Approved Research Projects
- 2022 – 2024: Research Grant Goldschmid-Jacobson Foundation, University of Basel: Neuroendocrine Neoplasms Methylation based Classifier (NEMESIS-study)
- 2021: Return Grant University Hospital Basel: Improving Therapeutic Options for Patients with Neuroendocrine Neoplasms
- 2019 – 2020: Early Postdoc.Mobility Grant Swiss National Science Foundation: Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients (IMPROVE-NET study)
Collaborations
National Collaborations
- Prof. Katharina Glatz / Jürgen Hench, Pathology, Universitätsspital Basel
- PD Dr. Raoul Droeser, Surgery, Universitätsspital Basel
- Dr. Svenja Nölting & Prof. Felix Beuschlein, Universitätsspital Zürich
- Prof. Beat Müller, Kantonsspital Aarau
- Dr. Stefan Fischli, Kantonsspital Luzern
- PD Dr. Stefan Bilz, Kantonsspital St. Gallen
- Prof. Anne Zanchi, Universitätsspital Lausanne (CHUV)
- Prof. Gregor Lindner, Spital Solothurn
- Prof. Jörg Leuppi, Kantonsspital Liestal
International Collaborations
- Dr. Hans Hofland, Erasmus Medical Center, Rotterdam, the Netherlands
- Prof. Ewout Hoorn, Erasmus Medical Center, Rotterdam, the Netherlands
- Prof. Volker Burst, Uniklinik Köln, Germany
- Prof. Alessandro Peri, Florence, Italy
- Prof. Darko Kastelan, University Hospital Centre Zagreb, Croatia
Ongoing Research Projects
- he NEMESIs-study: Neuroendocrine Neoplasms Methylation based Classifier
In collaboration with Prof. Mirjam Christ-Crain
- The HIT-study: Targeted correction of plasma sodium levels in hospitalized patients with hyponatremia - a randomized, controlled, parallel-group trial with blinded outcome assessment
- The CARGOx study: Copeptin after arginine infusion compared to copeptin after hypertonic saline infusion for the differential diagnosis of diabetes insipidus
- The EMPOWER study: Effects of the SGLT2 inhibitor empagliflozin in patients with euvolemic and hypervolemic hyponatremia – a monocentric randomized double-blind placebo-controlled trial